Stem Cell Company Stocks 9/6/09

The mixed bag for stem cell stocks continues. Pops seem to only occur with news on individual stocks.

Top Stem Cell Stock Performer(s) the Last Two Weeks:

- Brainstorm Cell Therapeutics (BCLI) = Up 293%; A stem cell production deal cause the stock to spike. The shares hit a 52 week high of $0.38, but has dropped quickly. I'd monitor this stock after a 50% retracement to see if this is just a flash in the pan.

Worst Stem Cell Stock Performer(s) the Last Two Weeks:

- MultiCell Technologies (MCET.OB) = Down -22%; This wasn't quite the biggest loser, but was the most predictable. As suggested during thr previous post, the gains didn't hold from the patent news.

Stem Cell Stocks Current Price and % Up or Down 8/24/09 - 9/4/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $2.35; Up 11%
Aastrom Biosciences (ASTM) = Cur Price: $0.43; Down -4%
BioTime, Inc. (BTIM) = Cur Price: $3.50; Up 13%
Celgene Corp (CELG) = Cur Price: $51.74; Down -3%
Cytori Therapeutics (CYTX) = Cur Price: $3.12; Down -3%
Geron Corp (GERN) = Cur Price: $7.21; Up 11%
ThermoGenesis (KOOL) = Cur Price: $0.62; Down -10%
Osiris Therapeutics (OSIR) = Cur Price: $12.21; Unchanged
StemCell Inc. (STEM) = Cur Price: $1.70; Up 4%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.155; Up 31%
Athersys Inc. (ATHX) = Cur Price: $0.98; Up 1%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.24; Up 293%
Bioheart Inc. (BHRT) = Cur Price: $0.77; Up 28%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.003; Down -3%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $2.25; Up 13%
Neuralstem (CUR) = Cur Price: $1.14; Up 5%
International Stem Cell (ISCO.OB) = Cur Price: $0.82; Unchanged
MultiCell Technologies (MCET.OB) = Cur Price: $0.0235; Down -22%
Pluristem Therapeutics (PSTI) = Cur Price: $1.31; Down -10%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.035; Down -27%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.003; Down -6%

Catalyst(s):

Still, nothing has changed from the last few months.

- M&A (mergers and acquisitions) activity will be key.